Pretomanid + Moxifloxacin + Pyrazinamide
PaMZ was the first novel multi-drug TB treatment to undergo clinical testing in the new regimen development paradigm. PaMZ was tested in the Phase 2a NC-001 trial, in which it killed TB bacteria faster when compared with the current TB regimen, as well as other experimental regimens over the first two weeks of treatment. It was subsequently tested in NC-002, in which it met its primary endpoint after eight weeks treatment. PaMZ has the potential to cure both TB and some forms of MDR-TB, simplifying and improving treatment. This regimen projects to be able to be effectively administered alongside common ARV treatments, thereby improving treatment options for patients co-infected with TB and HIV. It also shows promise for MDR-TB patients who are sensitive to the drugs in the regimen, reducing treatment time and costing just a fraction of the current MDR-TB treatment. Additionally, the PaMZ regimen can be administered in a fixed dose for all patients, and will therefore be simpler for health systems to deliver and patients to use.
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial